Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) and Lucira Health (NASDAQ:LHDXQ – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.
Insider and Institutional Ownership
88.5% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 15.7% of Lucira Health shares are held by institutional investors. 3.0% of Intellia Therapeutics shares are held by insiders. Comparatively, 30.4% of Lucira Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings and target prices for Intellia Therapeutics and Lucira Health, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Intellia Therapeutics | 0 | 3 | 15 | 0 | 2.83 |
| Lucira Health | 0 | 0 | 0 | 0 | N/A |
Risk and Volatility
Intellia Therapeutics has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, Lucira Health has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500.
Profitability
This table compares Intellia Therapeutics and Lucira Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Intellia Therapeutics | -854.92% | -41.64% | -33.93% |
| Lucira Health | N/A | N/A | N/A |
Earnings & Valuation
This table compares Intellia Therapeutics and Lucira Health’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Intellia Therapeutics | $52.12 million | 67.08 | -$474.19 million | ($5.46) | -7.24 |
| Lucira Health | $93.06 million | 0.00 | -$64.83 million | ($3.58) | 0.00 |
Lucira Health has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Lucira Health, indicating that it is currently the more affordable of the two stocks.
Summary
Lucira Health beats Intellia Therapeutics on 9 of the 13 factors compared between the two stocks.
About Intellia Therapeutics
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
About Lucira Health
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California. On February 22, 2023, Lucira Health, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
